The RAS-Effector Interaction as a Drug Target

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Approximately 33% of human cancers involve mutations in K-, N-, or HRAS genes.
• Mutated RAS proteins are constitutively activated, driving malignant transformation and tumor growth.
• Despite extensive research, no broadly effective FDA-approved drugs exist for RAS-driven cancers, leading to the 'undruggable' classification of RAS proteins.

Purpose of the Study:

• To review evidence supporting the feasibility of developing direct RAS inhibitors.
• To focus on compounds inhibiting RAS-effector interactions.
• To provide insights for developing clinical candidates for RAS-driven cancers.

Main Methods:

• Literature review of studies on direct-acting RAS inhibitors.
• Focus on compounds targeting RAS-effector signaling pathways.
• Analysis of evidence for inhibiting aberrant RAS protein activity.

Main Results:

• Mounting evidence suggests direct RAS inhibition is feasible.
• Compounds inhibiting RAS-effector interactions are a promising therapeutic strategy.
• These inhibitors target key signaling pathways sustaining malignant transformation.

Conclusions:

• Direct inhibitors of RAS proteins show potential for treating RAS-driven cancers.
• Targeting RAS-effector interactions offers a viable approach.
• Further research and development of these inhibitors are crucial for clinical application.